March 18, 2013 / 3:11 PM / 4 years ago

BRIEF-AstraZeneca CEO targets narrower R&D focus after revamp

LONDON, March 18 (Reuters) - AstraZeneca PLC CEO Pascal Soriot, in interview with Reuters: * CEO says prime focus of drug research and development will be oncology,

cardiovascular/metabolism and respiratory/inflammation * CEO says will be less investment in future on anti-infectives and

neuroscience * CEO says M&A will focus on rebuilding pipeline in key therapy areas * CEO says large-scale M&A not a priority, can return company to growth without

major acquisition * CEO says hopes current research and development overhaul is last substantial

restructuring of company

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below